Technical Advancement In Treatment Significantly Increase The Growth Of The Circulating Tumor Cell Market

What are the Circulating Tumor Cells?

CTC is the main tumor-shedding cancer cells that intravasate into the peripheral blood circulation system, causing metastasis. These are the cancer cells that have detached from the primary tumor and entered the bloodstream. CTC is considered to be a key component in the metastasis  

Drivers of Circulating Tumor Cells Market

Immune system invasion: Cancer cells can evade immune surveillance mechanisms and immune-mediated destruction they may down-regulate the cell surface proteins involved in immune recognition or activate immune checkpoint pathways, allowing them to escape immune detection and elimination 

Angiogenesis: angiogenesis is the process of new blood vessel formation. Tumors induce angiogenesis to ensure a sufficient blood supply for their growth. the newly formed blood vessels are often abnormal, leaky, and lack a proper basement membrane, allowing CTCs to enter the bloodstream more easily 

Restraining factors

Technological challenges: The development of accurate and reliable technologies for detecting and analyzing CTCs is complex. The technologies must be sensitive enough to detect rare CTCs among a large number of normal blood cells. Overcoming these technological challenges and ensuring consistent reproducible results

Heterogeneity of CTCs: CTCs exhibit significant heterogeneity both in terms of their molecular characteristics and physical properties. This heterogeneity makes it challenging to develop standardized approaches for their detection and analysis. The lack of standardized protocols and methods can hinder the widespread adoption of CTC- based diagnosis 

Clinical Utility and value proposition: Demonstrating the clinical utility and value proposition of CTCS-based technologies compared to existing diagnostic and monitoring approaches is essential for market adoption. It also has the ability to provide actionable information for treatment.

Recent development

Increased Growth in the tumor cell market:

As per the recent update from Global Newswire, revenue is expected to increase from $9.5 billion to $10.7 billion in 2023. As there is growth in the market size of cancer about $16.7 billion in 2027, due to the rising incidence of cancer and spreading the growing incidence of cancer is fueling the market growth.

Conclusion

CTCs offer a non-invasion method for monitoring cancer progression, assessing treatment response, and predicting patient outcomes by capturing and analyzing CTCs. Furthermore, the enumeration and characterization of CTCs have the potential to guide treatment decisions allowing for the selection.

Anushka Gore  

Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the medical devices & consumables industry. She has dedicated herself unraveling the intricate market trends and consumer behavio…